Kiniksa Pharmaceuticals
KNSA
104 hedge funds and large institutions have $383M invested in Kiniksa Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 9 closing their positions.
161% more call options, than puts
Call options by funds: $4.68M | Put options by funds: $1.79M
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
41% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 27
32% more capital invested
Capital invested by funds: $290M → $383M (+$92.7M)
13% more funds holding
Funds holding: 92 → 104 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.5% less ownership
Funds ownership: 87.3% → 86.8% (-0.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$10.5M |
| 2 |
Millennium Management
New York
|
+$7.77M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.26M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.62M |
| 5 |
Goldman Sachs
New York
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.7M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$7.89M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$5.63M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$3.23M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.54M |
KNSA Hedge Fund Activity: Q3 2022 in Review
104 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2022, worth a combined $383M — up 32% from $290M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new KNSA positions and 9 closed out — a net gain of 13 holders — while 38 added to existing stakes and 27 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $10.5M. The largest seller was Great Point Partners, exiting entirely with an estimated $11.7M sold.
- 104 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2022, up from 92 in Q2 2022.
- Funds reported $383M of Kiniksa Pharmaceuticals stock for Q3 2022, up 32% quarter-over-quarter.
- 22 funds opened new Kiniksa Pharmaceuticals positions in Q3 2022 and 9 closed out, a net change of +13 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $10.5M added.
- The largest Kiniksa Pharmaceuticals seller in Q3 2022 was Great Point Partners, an estimated $11.7M sold.
Based on aggregated 13F filings for Q3 2022.